My research focuses on personalised acute medicine, with sepsis as the focus. The aim is early recognition and biological subtyping of patients with (impending) sepsis, so that treatment can be tailored in time, and the development of therapies that prevent organ failure. Within the Acutelines biobank, I link clinical data (vital signs, waveforms) to multi-omics (RNA sequencing, proteomics) using machine learning, and validate subtypes in preclinical models to identify therapeutic targets. Mechanistic themes are immunometabolic dysregulation, mitochondrial and endothelial dysfunction and sepsis endotypes; hibernation biology serves as a blueprint for organ protection. I chair SepsisNet and am a board member of the European Group on the Immunology of Sepsis.
